Department of Defense Grant for Rapid Medical Clinical Trial Implementation

The FY23 PRMRP Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in one of the congressionally directed FY23 PRMRP Topic Areas and FY23 PRMRP Strategic Goals. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.